Bluejay Diagnostics, Inc. Revenue, Remaining Performance Obligation, Percentage
Bluejay Diagnostics, Inc. (BJDX) had Revenue, Remaining Performance Obligation, Percentage of 15.00% as of 2023-06-30, per its 10-Q filed 2023-08-14.
Discontinued › Notes
us-gaap:RevenueRemainingPerformanceObligationPercentage · last filed 2023-08-14
- 2023-06-30: Revenue, Remaining Performance Obligation, Percentage 15.00%.
| Period end | Revenue, Remaining Performance Obligation, Percentage |
|---|---|
| 2023-06-30 | 15.00% 10-Q · filed 2023-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OSR Health, Inc. (OSRH) | United States | $0.004B | -0.75 |
| Adagio Medical Holdings, Inc. (ADGM) | United States | $0.004B | |
| Autonomix Medical, Inc. (AMIX) | United States | $0.004B | |
| AETHLON MEDICAL INC (AEMD) | United States | $0.005B | |
| INTELLIGENT BIO SOLUTIONS INC. (INBS) | United States | $0.005B | |
| Beyond Air, Inc. (XAIR) | United States | $0.003B | -0.01 |
| Vivos Therapeutics, Inc. (VVOS) | United States | $0.003B | -0.26 |
| Sonoma Pharmaceuticals, Inc. (SNOA) | United States | $0.006B | -2.59 |
| NEXGEL, INC. (NXGL) | United States | $0.002B | |
| INVO Fertility, Inc. (IVF) | United States | $0.002B | -0.71 |